Protein kinase CK1δ expression and activity is involved in different pathological situations that include neuroinflammatory and
neurodegenerative diseases. For this reason,
protein kinase CK1δ has become a possible therapeutic target for these conditions. 5,6-fused bicyclic heteroaromatic systems that resemble
adenine of
ATP represent optimal scaffolds for the development of a new class of
ATP competitive CK1δ inhibitors. In particular, a new series of [1,2,4]triazolo[1,5-c]
pyrimidines and [1,2,4]triazolo[1,5-a][1,3,5]
triazines was developed. Some crucial interactors have been identified, such as the presence of a free amino group able to interact with the residues of the hinge region at the 5- and 7- positions of the [1,2,4]triazolo[1,5-c]
pyrimidine and [1,2,4]triazolo[1,5-a][1,3,5]
triazine scaffolds, respectively; or the presence of a 3-hydroxyphenyl or 3,5-dihydroxyphenyl moiety at the 2- position of both nuclei. Molecular modeling studies identified the key interactions involved in the inhibitor-
protein recognition process that appropriately fit with the outlined structure-activity relationship. Considering the fact that the CK1
protein kinase is involved in various pathologies in particular of the central nervous system, the interest in the development of new inhibitors permeable to the blood-brain barrier represents today an important goal in the pharmaceutical field. The best potent compound of the series is the 5-(7-amino-5-(benzylamino)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-2-yl)benzen-1,3-diol (compound 51, IC50 = 0.18 μM) that was predicted to have an intermediate ability to cross the membrane in our in vitro assay and represents an optimal starting point to both studies the therapeutic value of
protein kinase CK1δ inhibition and to develop new more potent derivatives.